3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
29
Other hematologic neoplasm
7
Plasma cell
1
Myeloid
1
CNS
1
Conditions
Glioblastoma
2
Brain Neoplasms
2
Primary Central Nervous System Lymphoma (PCNSL)
1
Neurologic Manifestations
1
Neuroectodermal Tumors, Primitive
1
Medulloblastoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Ependymoma
1
Central Nervous System Neoplasms
1
Interventions
Filgrastim
11
Temozolomide
9
Melphalan
9
Cyclophosphamide
9
Radiotherapy
7
Busulfan
7
Magnetic Resonance Spectroscopy
6
Rituximab
5
Psychiatric Rehabilitation
5
Methotrexate
5
Etoposide
5
Cytarabine
5
Carboplatin
5
sargramostim
4
fludarabine
4
etoposide phosphate
4
Thiotepa
4
Nivolumab
4
Methylprednisolone
4
Flow Cytometry
4
Alemtuzumab
4
Vincristine
3
Topotecan
3
Specimen Handling
3
Peripheral Blood Stem Cell Transplantation
3
Pemetrexed
3
Granulocyte Colony-Stimulating Factor
3
Early Intervention, Educational
3
Drug Therapy
3
Dexamethasone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
ibrutinib
×
CNS
×
Clear all
NCT04446962
2025-09-25
LOC-R01
Institut Curie
Phase 1/2
Active not recruiting
118 enrolled